Secondary endpoints include overall survival in the subpopulation of patients with epidermal growth factor receptor wild type, as well as progression-free survival and further assessment of the safety of the tivantinib/Tarceva combination

Its secondary objective will be to observe any antitumor activity, duration of response and progression-free survival...The study is designed primarily to test efficacy and safety of the drug, with secondary objectives measuring duration of response and progression-free survival

The study is designed to enroll about 105 patients, with a primary endpoint of progression-free survival

ImmunoGen Inc., of Waltham, Mass., said partner Roche AG, of Basel, Switzerland, disclosed top-line Phase II results showing that trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer patients significantly improved progression-free survival compared to Herceptin (trastuzumab) plus chemotherapy (docetaxel

The study, which is expected to enroll approximately 370 patients in North America and Europe, has a primary endpoint of progression-free survival

Based on overall survival data from the Phase IIb 003-A1 study, the company is changing the primary endpoint of the FOCUS trial from progression-free survival to overall survival

Progression-free survival and overall survival are the co-primary endpoints

The primary endpoint is progression-free survival

Progression-free survival and overall survival will be the co-primary endpoints

The primary endpoint is to determine the safety, dose-limiting toxicity and recommended Phase II dose, while secondary endpoints will assess overall response rate, as measured by RECIST criteria, as well as progression-free survival, overall survival and exploratory biomarkers...Objectives of the study include assessing the efficacy of oral PLX3397 as measured by overall response rate, as well as the duration of response, the disease control rate, progression-free survival, response biomarkers and

The co-primary endpoints will be progression-free survival and overall survival

The study is expected to enroll more than 100 patients and will compare IPI-926 to placebo, with progression-free survival as the primary endpoint

That trial will assess progression-free survival in about 240 patients in the Phase IIb portion, and results will be used to inform the choice of patient subpopulation for the Phase III portion, which will measure overall survival and enroll between 400 patients to 600 patients

The primary endpoint of the study, which will take place in more than 20 countries, is progression-free survival

Secondary endpoints include progression-free survival, time to progression and overall response rate

The trial is expected to start later this quarter and will measure progression-free survival as the primary endpoint

The primary endpoint of the trial is progression-free survival

Novartis AG, of Basel, Switzerland, said data from the Phase III RADIANT-3 trial showed that mTOR inhibitor Afinitor (everolimus) plus best supportive care more than doubled progression-free survival vs

The study showed that those who received that treatment regimen had greater progression-free survival compared to women receiving chemotherapy alone